1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Infectious Diseases Market Size Growth Rate by Type: 2020 VS 2026
  • 1.2.2 Antibacterial drugs
  • 1.2.3 Antiviral drugs
  • 1.2.4 Antifungal drugs
  • 1.2.5 Antiparasitic drugs
• 1.3 Market by Application
  • 1.3.1 Global Infectious Diseases Market Share by Application: 2020 VS 2026
  • 1.3.2 Acquired Immune Deficiency Syndrome
  • 1.3.3 Hepatitis B
  • 1.3.4 Hepatitis C
  • 1.3.5 Human Papillomavirus
  • 1.3.6 Hospital acquired Methicillin-resistant Staphylococcus aureus infection
  • 1.3.7 Chlamydia trachomatis and Neisseria Gonorrhea
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Infectious Diseases Market Perspective (2015-2026)
• 2.2 Global Infectious Diseases Growth Trends by Regions
  • 2.2.1 Infectious Diseases Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Infectious Diseases Historic Market Share by Regions (2015-2020)
  • 2.2.3 Infectious Diseases Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Infectious Diseases Players by Market Size
  • 3.1.1 Global Top Infectious Diseases Players by Revenue (2015-2020)
  • 3.1.2 Global Infectious Diseases Revenue Market Share by Players (2015-2020)
• 3.2 Global Infectious Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Infectious Diseases Revenue
• 3.4 Global Infectious Diseases Market Concentration Ratio
  • 3.4.1 Global Infectious Diseases Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Infectious Diseases Revenue in 2019
• 3.5 Key Players Infectious Diseases Area Served
• 3.6 Key Players Infectious Diseases Product Solution and Service
• 3.7 Date of Enter into Infectious Diseases Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Infectious Diseases Breakdown Data by Type (2015-2026)

• 4.1 Global Infectious Diseases Historic Market Size by Type (2015-2020)
• 4.2 Global Infectious Diseases Forecasted Market Size by Type (2021-2026)

5 Infectious Diseases Breakdown Data by Application (2015-2026)

• 5.1 Global Infectious Diseases Historic Market Size by Application (2015-2020)
• 5.2 Global Infectious Diseases Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Infectious Diseases Market Size (2015-2026)
• 6.2 North America Infectious Diseases Market Size by Type (2015-2020)
• 6.3 North America Infectious Diseases Market Size by Application (2015-2020)
• 6.4 North America Infectious Diseases Market Size by Country (2015-2020)
  • 6.4.1 United States
  • 6.4.2 Canada

7 Europe

• 7.1 Europe Infectious Diseases Market Size (2015-2026)
• 7.2 Europe Infectious Diseases Market Size by Type (2015-2020)
• 7.3 Europe Infectious Diseases Market Size by Application (2015-2020)
• 7.4 Europe Infectious Diseases Market Size by Country (2015-2020)
  • 7.4.1 Germany
  • 7.4.2 France
  • 7.4.3 U.K.
  • 7.4.4 Italy
  • 7.4.5 Russia
  • 7.4.6 Nordic
  • 7.4.7 Rest of Europe

8 China

• 8.1 China Infectious Diseases Market Size (2015-2026)
• 8.2 China Infectious Diseases Market Size by Type (2015-2020)
• 8.3 China Infectious Diseases Market Size by Application (2015-2020)
• 8.4 China Infectious Diseases Market Size by Region (2015-2020)
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 South Korea
  • 8.4.4 Southeast Asia
  • 8.4.5 India
  • 8.4.6 Australia
  • 8.4.7 Rest of Asia-Pacific

9 Japan

• 9.1 Japan Infectious Diseases Market Size (2015-2026)
• 9.2 Japan Infectious Diseases Market Size by Type (2015-2020)
• 9.3 Japan Infectious Diseases Market Size by Application (2015-2020)
• 9.4 Japan Infectious Diseases Market Size by Country (2015-2020)
  • 9.4.1 Mexico
  • 9.4.2 Brazil

10 Southeast Asia

• 10.1 Southeast Asia Infectious Diseases Market Size (2015-2026)
• 10.2 Southeast Asia Infectious Diseases Market Size by Type (2015-2020)
• 10.3 Southeast Asia Infectious Diseases Market Size by Application (2015-2020)
• 10.4 Southeast Asia Infectious Diseases Market Size by Country (2015-2020)
  • 10.4.1 Turkey
  • 10.4.2 Saudi Arabia
  • 10.4.3 UAE
  • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

• 11.1 F. Hoffmann-La Roche
  • 11.1.1 F. Hoffmann-La Roche Company Details
  • 11.1.2 F. Hoffmann-La Roche Business Overview
  • 11.1.3 F. Hoffmann-La Roche Infectious Diseases Introduction
  • 11.1.4 F. Hoffmann-La Roche Revenue in Infectious Diseases Business (2015-2020))
  • 11.1.5 F. Hoffmann-La Roche Recent Development
• 11.2 Gilead Sciences
  • 11.2.1 Gilead Sciences Company Details
  • 11.2.2 Gilead Sciences Business Overview
  • 11.2.3 Gilead Sciences Infectious Diseases Introduction
  • 11.2.4 Gilead Sciences Revenue in Infectious Diseases Business (2015-2020)
  • 11.2.5 Gilead Sciences Recent Development
• 11.3 GlaxoSmithKline
  • 11.3.1 GlaxoSmithKline Company Details
  • 11.3.2 GlaxoSmithKline Business Overview
  • 11.3.3 GlaxoSmithKline Infectious Diseases Introduction
  • 11.3.4 GlaxoSmithKline Revenue in Infectious Diseases Business (2015-2020)
  • 11.3.5 GlaxoSmithKline Recent Development
• 11.4 Johnson & Johnson
  • 11.4.1 Johnson & Johnson Company Details
  • 11.4.2 Johnson & Johnson Business Overview
  • 11.4.3 Johnson & Johnson Infectious Diseases Introduction
  • 11.4.4 Johnson & Johnson Revenue in Infectious Diseases Business (2015-2020)
  • 11.4.5 Johnson & Johnson Recent Development
• 11.5 Merck
  • 11.5.1 Merck Company Details
  • 11.5.2 Merck Business Overview
  • 11.5.3 Merck Infectious Diseases Introduction
  • 11.5.4 Merck Revenue in Infectious Diseases Business (2015-2020)
  • 11.5.5 Merck Recent Development
• 11.6 Pfizer
  • 11.6.1 Pfizer Company Details
  • 11.6.2 Pfizer Business Overview
  • 11.6.3 Pfizer Infectious Diseases Introduction
  • 11.6.4 Pfizer Revenue in Infectious Diseases Business (2015-2020)
  • 11.6.5 Pfizer Recent Development
• 11.7 AbbVie
  • 11.7.1 AbbVie Company Details
  • 11.7.2 AbbVie Business Overview
  • 11.7.3 AbbVie Infectious Diseases Introduction
  • 11.7.4 AbbVie Revenue in Infectious Diseases Business (2015-2020)
  • 11.7.5 AbbVie Recent Development
• 11.8 Astellas Pharma
  • 11.8.1 Astellas Pharma Company Details
  • 11.8.2 Astellas Pharma Business Overview
  • 11.8.3 Astellas Pharma Infectious Diseases Introduction
  • 11.8.4 Astellas Pharma Revenue in Infectious Diseases Business (2015-2020)
  • 11.8.5 Astellas Pharma Recent Development
• 11.9 AstraZeneca
  • 11.9.1 AstraZeneca Company Details
  • 11.9.2 AstraZeneca Business Overview
  • 11.9.3 AstraZeneca Infectious Diseases Introduction
  • 11.9.4 AstraZeneca Revenue in Infectious Diseases Business (2015-2020)
  • 11.9.5 AstraZeneca Recent Development
• 11.10 Bayer
  • 11.10.1 Bayer Company Details
  • 11.10.2 Bayer Business Overview
  • 11.10.3 Bayer Infectious Diseases Introduction
  • 11.10.4 Bayer Revenue in Infectious Diseases Business (2015-2020)
  • 11.10.5 Bayer Recent Development
• 11.11 Bristol-Myers Squibb
  • 10.11.1 Bristol-Myers Squibb Company Details
  • 10.11.2 Bristol-Myers Squibb Business Overview
  • 10.11.3 Bristol-Myers Squibb Infectious Diseases Introduction
  • 10.11.4 Bristol-Myers Squibb Revenue in Infectious Diseases Business (2015-2020)
  • 10.11.5 Bristol-Myers Squibb Recent Development
• 11.12 Chimerix Pharmaceuticals
  • 10.12.1 Chimerix Pharmaceuticals Company Details
  • 10.12.2 Chimerix Pharmaceuticals Business Overview
  • 10.12.3 Chimerix Pharmaceuticals Infectious Diseases Introduction
  • 10.12.4 Chimerix Pharmaceuticals Revenue in Infectious Diseases Business (2015-2020)
  • 10.12.5 Chimerix Pharmaceuticals Recent Development
• 11.13 Cubist
  • 10.13.1 Cubist Company Details
  • 10.13.2 Cubist Business Overview
  • 10.13.3 Cubist Infectious Diseases Introduction
  • 10.13.4 Cubist Revenue in Infectious Diseases Business (2015-2020)
  • 10.13.5 Cubist Recent Development
• 11.14 Eli Lilly
  • 10.14.1 Eli Lilly Company Details
  • 10.14.2 Eli Lilly Business Overview
  • 10.14.3 Eli Lilly Infectious Diseases Introduction
  • 10.14.4 Eli Lilly Revenue in Infectious Diseases Business (2015-2020)
  • 10.14.5 Eli Lilly Recent Development
• 11.15 Isis Pharmaceuticals
  • 10.15.1 Isis Pharmaceuticals Company Details
  • 10.15.2 Isis Pharmaceuticals Business Overview
  • 10.15.3 Isis Pharmaceuticals Infectious Diseases Introduction
  • 10.15.4 Isis Pharmaceuticals Revenue in Infectious Diseases Business (2015-2020)
  • 10.15.5 Isis Pharmaceuticals Recent Development
• 11.16 Mitsubishi Tanabe Pharma
  • 10.16.1 Mitsubishi Tanabe Pharma Company Details
  • 10.16.2 Mitsubishi Tanabe Pharma Business Overview
  • 10.16.3 Mitsubishi Tanabe Pharma Infectious Diseases Introduction
  • 10.16.4 Mitsubishi Tanabe Pharma Revenue in Infectious Diseases Business (2015-2020)
  • 10.16.5 Mitsubishi Tanabe Pharma Recent Development
• 11.17 Novartis
  • 10.17.1 Novartis Company Details
  • 10.17.2 Novartis Business Overview
  • 10.17.3 Novartis Infectious Diseases Introduction
  • 10.17.4 Novartis Revenue in Infectious Diseases Business (2015-2020)
  • 10.17.5 Novartis Recent Development
• 11.18 Sanofi
  • 10.18.1 Sanofi Company Details
  • 10.18.2 Sanofi Business Overview
  • 10.18.3 Sanofi Infectious Diseases Introduction
  • 10.18.4 Sanofi Revenue in Infectious Diseases Business (2015-2020)
  • 10.18.5 Sanofi Recent Development
• 11.19 Vertex
  • 10.19.1 Vertex Company Details
  • 10.19.2 Vertex Business Overview
  • 10.19.3 Vertex Infectious Diseases Introduction
  • 10.19.4 Vertex Revenue in Infectious Diseases Business (2015-2020)
  • 10.19.5 Vertex Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer

Global Infectious Diseases Scope and Market Size
Infectious Diseases market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Infectious Diseases market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Market segment by Type, the product can be split into
Antibacterial drugs
Antiviral drugs
Antifungal drugs
Antiparasitic drugs

Market segment by Application, split into
Acquired Immune Deficiency Syndrome
Hepatitis B
Hepatitis C
Human Papillomavirus
Hospital acquired Methicillin-resistant Staphylococcus aureus infection
Chlamydia trachomatis and Neisseria Gonorrhea

Based on regional and country-level analysis, the Infectious Diseases market has been segmented as follows:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Infectious Diseases market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study
F. Hoffmann-La Roche
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck
Pfizer
AbbVie
Astellas Pharma
AstraZeneca
Bayer
Bristol-Myers Squibb
Chimerix Pharmaceuticals
Cubist
Eli Lilly
Isis Pharmaceuticals
Mitsubishi Tanabe Pharma
Novartis
Sanofi
Vertex